Cardiotoxicity in patients treated with acalabrutinib von Langerbeins, Petra

Volltext

Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic von Langerbeins, Petra, Eichhorst, Barbara

Volltext

Secondary immunodeficiency in lymphoproliferative malignancies von Friman, Vanda, Winqvist, Ola, Blimark, Cecilie, Langerbeins, Petra, Chapel, Helen, Dhalla, Fatima

Volltext

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia von Mellinghoff, Sibylle C., Robrecht, Sandra, Mayer, Leonie, Weskamm, Leonie M., Dahlke, Christine, Gruell, Henning, Vanshylla, Kanika, Schlösser, Hans A., Thelen, Martin, Fink, Anna-Maria, Fischer, Kirsten, Klein, Florian, Addo, Marylyn M., Eichhorst, Barbara, Hallek, Michael, Langerbeins, Petra

Volltext

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial von Herling, Carmen D., Cymbalista, Florence, Groß-Ophoff-Müller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Leprêtre, Stéphane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Döhner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Böttcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael, Levy, Vincent

Volltext

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial von Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna Maria, Goede, Valentin, Herling, Carmen Diana, Cramer, Paula, Langerbeins, Petra, von Tresckow, Julia, Engelke, Anja, Maurer, Christian, Kovacs, Gabor, Herling, Marco, Tausch, Eugen, Kreuzer, Karl-Anton, Eichhorst, Barbara, Böttcher, Sebastian, Seymour, John F., Ghia, Paolo, Marlton, Paula, Kneba, Michael, Wendtner, Clemens-Martin, Döhner, Hartmut, Stilgenbauer, Stephan, Hallek, Michael

Volltext

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCL... von Cramer, Paula, Isfort, Susanne, Bahlo, Jasmin, Stilgenbauer, Stephan, Döhner, Hartmut, Bergmann, Manuela, Stauch, Martina, Kneba, Michael, Lange, Elisabeth, Langerbeins, Petra, Pflug, Natali, Kovacs, Gabor, Goede, Valentin, Fink, Anna-Maria, Elter, Thomas, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael, Eichhorst, Barbara

Volltext

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two P... von Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Günter, Ritgen, Matthias, Kneba, Michael, Döhner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Böttcher, Sebastian

Volltext

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia von Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fürstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Müller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO) von Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial von Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Al-Sawaf, Othman, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Tausch, Eugen, Seiler, Till, Fischer von Weikersthal, Ludwig, Hebart, Holger, Kreuzer, Karl-Anton, Böttcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy von Fürstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Tresckow, Julia Von, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Döhner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Hallek, Michael, Theurich, Sebastian

Volltext

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GC... von Kutsch, Nadine, Ligtvoet, Rudy, Robrecht, Sandra, Linde, Hartmut, Illmer, Thomas, Doerfel, Steffen, Lipke, Joerg, Aldaoud, Ali, Schlag, Rudolf, Dengler, Jolanta, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Eichhorst, Barbara F., Hallek, Michael, Fischer, Kirsten, Fink, Anna Maria

Volltext

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-... von Cheson, Bruce D., Shouse, Geoffrey P., Assouline, Sarit, Lewis, Katharine L., Hawkes, Eliza A, Munir, Talha, Davies, Andrew S., Langerbeins, Petra, Tam, Constantine S., Gregory, Gareth P., Choi, Michael Y., Sun, William, Atwal, Siminder K., Hong, Wan-Jen, Sarkozy, Clémentine

Volltext

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag T... von Furstenau, Moritz, Giza, Adam, Fink, Anna-Maria, Robrecht, Sandra, Weiss, Jonathan, Kleinert, Fanni, Schneider, Christof, Tausch, Eugen, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara F., Hallek, Michael, Cramer, Paula

Volltext

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CL... von Yosifov, Deyan Y., Robrecht, Sandra, Giza, Adam, Riecke, Armin, Schneider, Christof, Jebaraj, Billy, Jumaa, Hassan, Young, Marc, Müller, Lothar, Vehling-Kaiser, Ursula, Eckart, Michael J., Freier, Werner, Schöttker, Björn, Gaska, Tobias, Reiser, Marcel, Fink, Anna-Maria, Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, Langerbeins, Petra, Stilgenbauer, Stephan, Tausch, Eugen

Volltext

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL von Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Fink, A., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Schneider, C., Müller, L., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Zahn, M., Dörfel, S., Eckart, M. J., Staib, P., Behlendorf, T., Hensel, M., Hebarth, H., Klaproth, H., Block, A., Liersch, R., Hauch, U., Heinrich, B., Wendtner, C., Fischer, K., Stilgenbauer, S., Eichhorst, B., Hallek, M.

Volltext

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial von von Tresckow, Julia, Cramer, Paula, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Fürstenau, Moritz, Illmer, Thomas, Klaproth, Holger, Tausch, Eugen, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Böttcher, Sebastian, Eichhorst, Barbara F., Hallek, Michael

Volltext

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group von Simon, Florian, Ligtvoet, Rudy, Robrecht, Sandra, Cramer, Paula, Kutsch, Nadine, Furstenau, Moritz, Goede, Valentin, Von Tresckow, Julia, Langerbeins, Petra, Fink, Anna-Maria, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Wendtner, Clemens-Martin, Ritgen, Matthias, Dreyling, Martin, Müller, Lothar, Jacobasch, Lutz, Heinz, Werner, Vehling-Kaiser, Ursula, Sivcheva, Liliya, Böttcher, Sebastian, Dreger, Peter, Illmer, Thomas, Gregor, Michael, Staber, Philipp Bernhard, Stilgenbauer, Stephan, Niemann, Carsten Utoft, Kater, Arnon P., Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, Al-Sawaf, Othman

Volltext

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations von Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, Tresckow, Julia, Al‐Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kater, Arnon P., Spek, Ellen, Niemann, Carsten Utoft, Cunha‐Bang, Caspar, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara

Volltext